Compounds · Metabolic & weight · Treatment of HIV-associated lipodystrophy
Tesamorelin (Egrifta)
TH9507, Egrifta, trans-3-hexenoyl-GHRH(1-44)-NH2
A synthetic GHRH analogue, marketed as Egrifta and FDA-approved to reduce excess abdominal fat in HIV patients with lipodystrophy, by prompting the pituitary to release growth hormone that acts on fat tissue.
2 mg nightly
Research score 90/100. Reference only, not a prescription.
- Fat Loss
- Growth Hormone Release
- Metabolic Enhancement
- Anti-aging
- Gut Health
- Hormone Regulation
- US status
- Prescription Only
- Approval
- FDA Approved
- Evidence
- FDA Approved (Egrifta).
- Research score
- 90 / 100
- Indication
- Excess abdominal fat in HIV-associated lipodystrophy
- Origin
- Canada
- Source category
- Digestive System
- Status group
- Approved / prescription
Mechanism
Binds GHRH receptors on pituitary cells to stimulate GH synthesis and release, raising IGF-1 and promoting fat breakdown especially in visceral fat, with structural changes giving it greater stability and half-life than natural GHRH while preserving receptor specificity.
Safety file
Injection-site reactions and hypersensitivity can occur; risk of glucose intolerance or diabetes; raises IGF-1, requiring cancer monitoring.
- Injection site reactions
- Joint pain
- Muscle pain
- Numbness in extremities
- Mild nausea
- Sleep disturbances
Reconstitution
| Vial | 2 mL water | 3 mL water |
|---|---|---|
| 10 mg | 5 mg/mL | 3.33 mg/mL |
| 20 mg | 10 mg/mL | 6.67 mg/mL |
Reconstitutes with standard bacteriostatic water. Add the water slowly down the wall and roll the vial gently between your palms for about 30 seconds until the powder dissolves. It foams easily, so never shake it. If a stubborn lot will not clear with bac water alone, a known workaround is adding about 0.1 mL of acetic acid first, then topping up with bac water to the target volume. Most vials never need this.
- Use bacteriostatic water as the diluent.
- Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
- Swirl gently to mix, then leave it to dissolve. Do not shake.
- Give it a few minutes. The finished solution should be clear and colourless.
- Roll the vial gently between your palms for about 30 seconds. Do not shake, since it foams readily.
- A little foaming on mixing is normal. Let it settle for a minute.
- Only if it will not fully dissolve in bac water alone: add about 0.1 mL of acetic acid first, swirl until clear, then add bac water to reach your target volume.
Protocol
Route: Subcutaneous
Standard protocol (subcutaneous)
- 2 mg once daily, injected at night
- This is the studied clinical dose for reducing visceral fat
- The label dose is 2 mg daily (1.4 mg for the Egrifta SV formulation), into the abdomen. Night-time, empty-stomach timing is common practice, not a label rule
Dosing detail
- Standard dose is 2 mg once daily at night. Some run 1 mg daily as a lighter approach.
- Inject on an empty stomach for the cleanest GH pulse.
- Visceral fat reduction is gradual, measured over months, not weeks.
- Mild water retention or joint achiness can appear early and usually settles.
Duration
- Run for at least 3 months given how gradually it works. Many keep it going longer while tracking how they look and feel.
Notes
- A GHRH analogue used mainly for reducing visceral fat.
- Inject subcutaneously and rotate sites.
- Mild water retention or joint achiness can show up early and usually settles.
Storage and handling
- Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
- Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
- Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
- If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.
NovaEvum vial
Worksheet
2 mL bacteriostatic water into 10 mg gives 5 mg/mL. A 1 mg amount is 20 units; 2 mg is 40 units.
- Catalog fill
- 10 mg
- Typical water
- 2 mL
- Route
- Subcutaneous, abdomen
- Cycle
- 8–12 weeks, then reassess. Not typically pulsed like Ipamorelin.
| Step | Amount | Frequency | Notes |
|---|---|---|---|
| Label dose (Egrifta) | 2 mg | Once daily | 40 units from a 2 mL reconstitution |
| Lighter amount | 1 mg | Once daily | 20 units |
- Sometimes paired with a secretagogue (Ipamorelin) rather than another GHRH analog.
- GHRH analogs are not interchangeable milligram-for-milligram with CJC-1295.
- Bacteriostatic water: 20–25 °C. Do not refrigerate the diluent.
- Amounts on this sheet are reconstitution math for the vial, not a recommendation.